Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ALIZÉ PHARMA<br />
15 Chemin du Saquin<br />
Espace Européen - BAT G<br />
69130 ECULLY - FRANCE<br />
Phone: +33 4 72 18 94 28<br />
Fax: +33 4 78 33 36 29<br />
Email: tabrib<strong>at</strong>@alz-pharma.com<br />
vwesley@alz-pharma.com<br />
Web site: www-alz-pharma.com<br />
Contact: Valérie WESLEY<br />
The Alizé Pharma Group is specialized in the development of innov<strong>at</strong>ive<br />
biopharmaceuticals for the tre<strong>at</strong>ment of metabolic diseases and cancer. Its<br />
management is made up of a team of drug development experts and a board of<br />
directors offering wide intern<strong>at</strong>ional experience. The two main products currently in<br />
development include a ghrelin-derived peptide targeting type II diabetes and other<br />
cardiovascular risks, and a PEGyl<strong>at</strong>ed recombinant L-asparaginase for the tre<strong>at</strong>ment<br />
of acute lymphoblastic leukemia.<br />
ALMETIS<br />
4 rue Boussingault<br />
67000 STRASBOURG - FRANCE<br />
Phone: +33 3 68 85 31 77<br />
Email: contact@almetisbio.com<br />
Web site: www.almetisbio.com<br />
Contact: Marjorie SIDHOUM<br />
Almetis is dedic<strong>at</strong>ed to the discovery and the development of innov<strong>at</strong>ive metal-based<br />
therapeutics in oncology up to proof of concept in man. Our expertise is unique on<br />
organometallic drugs th<strong>at</strong> have demonstr<strong>at</strong>ed anticancer properties answering to<br />
usual drawbacks of chemotherapies and constituting a new class of anticancer drugs.<br />
Our mission is to provide therapeutic solutions to unmet medical needs via innov<strong>at</strong>ive<br />
tre<strong>at</strong>ment triggering specific mechanism. Almetis’ pipeline g<strong>at</strong>hers new chemical<br />
entities from hits to preclinical candid<strong>at</strong>es and is open to develop collabor<strong>at</strong>ive<br />
programs with partners.<br />
26
Change language